Abcam, ab263269, Human MYL6B (MLC1SA) knockout HEK-293T cell lysate

Size: 1Kit
MYL6B KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, Homozygous: 2 bp insertion in exon 2.
Key facts
Cell type:HEK-293T,
Species or organism:Human,
Tissue:Kidney,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, Homozygous: 2 bp insertion in exon 2.

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-MYL6B, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Zygosity-Homozygous, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
MLC1SA also known as myosin light chain 1 slow-twitch muscle isoform plays a significant role in muscle contraction. It binds to myosin heavy chains in muscle fibers regulating the actin-myosin interaction essential for muscle contraction. MLC1SA has a molecular mass of approximately 18 kDa and shows expression predominantly in slow-twitch muscle fibers which are important for endurance activities. It also exhibits expression in certain cardiac tissues highlighting its function beyond skeletal muscles.
Biological function summary
MLC1SA contributes to muscle contraction regulation by modulating the interaction between actin and myosin. It is part of a complex that includes myosin heavy chains and other associated proteins. Through phosphorylation events MLC1SA adjusts the sensitivity of muscle fibers to calcium which is critical for the fine-tuning of muscle responses to stimuli. This subtle modulation is important for activities that rely on sustained muscle tension.
Pathways
Myosin light chain signaling involves MLC1SA as a central component in muscular contraction pathways. It plays a role in the myosin-actin crossbridge cycle aiding the efficient conversion of ATP into mechanical work. MLC1SA interacts with other proteins such as myosin heavy chains and calmodulin. These interactions are critical in pathways like the calcium signaling pathway and muscle contraction pathway where calcium ions serve as triggers for changes in muscle cell activity.
Defects or alterations in MLC1SA expression or function can relate to muscular dystrophies and myopathies. These conditions often involve muscle weakness and reduced endurance where MLC1SA disruption alters normal muscle function. Moreover cardiomyopathies can show links with this protein especially when considering the interaction with myosin heavy chains and tropomyosin. Alterations in these interactions may disrupt cardiac muscle contraction contributing to disease pathogenesis.